Search Prime Contracts

75N91023C00030

Definitive Contract

Overview

Government Description
TOPIC 426: ATLASCOPE: COMPOSABLE VISUALIZATION TOOLS FOR MULTISCALE INTEGRATIVE BIOLOGY
Awardee
Kitware
Awarding / Funding Agency
National Cancer Institute (NCI) [HHS - NIH]
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN13 - Health R&D Services; Health Care Services; Experimental Development
Place of Performance
Clifton Park, NY 12065 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Est. Average FTE
4
Related Opportunity
BAA 75N91022R00027
Kitware was awarded Definitive Contract 75N91023C00030 (75N910-23-C-00030) for Topic 426: Atlascope: Composable Visualization Tools For Multiscale Integrative Biology worth up to $1,499,969 by National Cancer Institute in September 2023. The contract has a duration of 2 years and was awarded with a Small Business Total set aside with NAICS 541715 and PSC AN13 via direct negotiation acquisition procedures with 1 bid received.

SBIR Details

Research Type
Small Business Innovation Research Program (SBIR) Phase II
Title
TOPIC 426: ATLASCOPE: COMPOSABLE VISUALIZATION TOOLS FOR MULTISCALE INTEGRATIVE BIOLOGY
Abstract
In Phase I, we were able to prototype several features for Atlascope and demonstrate that they form a plausible system in which to conduct multiscale biological workflows and visualizations. In Phase II, we will aim to scale up our Phase I success in several directions: technologically, we will aim to harden the features and the web application we have developed to host our Phase I experiments; biologically, we will aim to bring in more production data and reproduce more of our research partners' workflows; commercially, we will market the new capability to interested parties within and without our network of customers and research partners.e
Research Objective
The goal of phase II is to continue the R&D efforts initiated in Phase I. Funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the project proposed in Phase II.
Topic Code
426
Agency Tracking Number
75N91023C00030
Solicitation Number
BAA 75N91022R00027
Contact
David Edsforth

Status
(Complete)

Last Modified 9/11/23
Period of Performance
9/15/23
Start Date
9/14/25
Current End Date
9/14/25
Potential End Date
100% Complete

Obligations
$1.5M
Total Obligated
$1.5M
Current Award
$1.5M
Potential Award
100% Funded

Award Hierarchy

Definitive Contract

75N91023C00030

Subcontracts

-

Activity Timeline

Interactive chart of timeline of amendments to 75N91023C00030

Subcontract Awards

Disclosed subcontracts for 75N91023C00030

People

Suggested agency contacts for 75N91023C00030

Competition

Number of Bidders
1
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

Other Categorizations

Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
DK6LPWMS5LP5
Awardee CAGE
1DKA7
Agency Detail
Awarding Office
75N910 NIH NCI
Funding Office
75N910
Created By
hhsjfrench
Last Modified By
hhsjfrench
Approved By
hhssmclaurin

Legislative

Legislative Mandates
None Applicable
Performance District
NY-20
Senators
Kirsten Gillibrand
Charles Schumer
Representative
Paul Tonko

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Other services from non-Federal sources (25.2) $1,499,969 100%
Modified: 9/11/23